Related Experiment Video

Updated: Aug 19, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

[Treatment of androgen-independent hormone refractory prostate cancer using docetaxel]

Yasuhide Miyoshi1, Hiroji Uemura, Yoshinobu Kubota

  • 1Department of Urology, Yokohama City University Graduate School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|February 18, 2005
PubMed

Insights

Hormone-refractory prostate cancer (HRPC) is challenging to treat. Docetaxel shows significant anti-tumor effects in HRPC patients, offering a new treatment option.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Metastatic prostate cancer often becomes resistant to androgen ablation therapy, leading to hormone-refractory prostate cancer (HRPC).
  • Optimal treatment strategies for HRPC remain an unmet clinical need.
  • Docetaxel is a taxane agent with demonstrated anti-tumor activity.

Purpose of the Study:

  • To review the efficacy of docetaxel in treating hormone-refractory prostate cancer.
  • To highlight the mechanism of action and clinical applications of docetaxel in HRPC.

Main Methods:

  • Review of preclinical and clinical studies on docetaxel in HRPC.
  • Analysis of docetaxel's mechanism of action, including microtubule stabilization and apoptosis induction.
  • Examination of combination therapies involving docetaxel.

Main Results:

  • Docetaxel as a single agent exhibits significant anti-tumor effects in HRPC patients.
  • Combination of docetaxel with estramustine or other antimicrotubular agents enhances cytotoxicity.
  • FDA approval of docetaxel in combination with prednisone for advanced metastatic prostate cancer in 2004.

Conclusions:

  • Docetaxel is an effective therapeutic option for patients with hormone-refractory prostate cancer.
  • Combination therapies with docetaxel may offer improved outcomes for HRPC.
  • Docetaxel represents a significant advancement in the treatment of advanced prostate cancer.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...